E-Cigarettes vs. Nicotine Therapy to Stop Smoking

E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy according to this randomized study recently published in the New England Journal of Medicine (NEJM). Both must be accompanied by medical and psychological support for optimal results.

Enfermedad pulmonar y cigarrillos electrónicos: Nuevos dispositivos con nuevas enfermedadesWhile e-cigarettes are commonly used as a smoking cessation strategy, evidence is limited regarding their effectiveness as compared with other strategies such as approved nicotine products (chewing gum, candy, patches, etc.) that act as nicotine replacement to help patients stop smoking permanently.

 

A total of 886 participants attending dedicated U.K. stop-smoking services underwent randomization to either nicotine-replacement products (different combinations or presentations) for 3 months or an e-cigarette (a second-generation refillable e-cigarette with one bottle of nicotine e-liquid [18 mg/mL]). Flavor and strength were left to the patients’ choice. Treatment was to be followed for at least 4 weeks.


Read also: E-Cigarettes: No Definitive Evidence on Their Potential Cardiovascular Effect, but Some Suggest Caution.


For both treatment arms, treatment included counseling follow-up for at least 4 weeks.

 

The primary outcome was sustained abstinence for one year, which was validated biochemically at the final follow-up visit. Participants who were lost to follow-up or did not access biochemical validation were considered to not be abstinent.

 

The abstinence rate at one year was 18% in the e-cigarette group vs. 9.9% in the nicotine-replacement group (relative risk [RR]: 1.83; 95% confidence interval [CI]: 1.30 to 2.58; p < 0.001). While the abstinence rate for e-cigarettes almost doubled the rate for nicotine-replacement therapy, 18% is still very low and we should insist so that more patients can quit smoking for good.


Read also: Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference.


The most frequently reported events were throat or mouth irritation for the e-cigarette group and nausea for the nicotine-replacement group.

 

Symptoms such as cough and phlegm production were also minor in the e-cigarette group.

 

There were no differences between groups in the incidence of bronchospasm or dyspnea.

 

Conclusion

E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy when both were accompanied by psychological and medical advice.

 

Original title: A Randomized Trial of E-Cigarettes Versus Nicotine-Replacement Therapy.

Reference: Peter Hajek et al. N Engl J Med. 2019 Feb 14;380(7):629-637.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...